X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
AU-007 is a human IgG1 monoclonal antibody designed to harness the power of interleukin-2 (IL-2) to eradicate solid tumors. It is being evaluated in phase 1/2 clinical trials for the treatment of advanced melanoma, advanced renal cell carcinoma.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 25, 2024
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. It is under phase 1/2 clinical development for the treatment of solid tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
The funds will be used to advance Aulos’ lead human monoclonal antibody candidate, AU-007 that is highly selective to the CD25-binding portion of IL-2, through its initial Phase 2 clinical study in solid tumor cancers.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Apple Tree Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing August 01, 2023
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2023
Details:
Proleukin® (aldesleukin), a form of interleukin-2, is indicated for the treatment of adults with metastatic melanoma (mM) and metastatic renal cell carcinoma (mRCC).
Lead Product(s): Aldesleukin
Therapeutic Area: Oncology Product Name: Proleukin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Iovance Biotherapeutics
Deal Size: $206.3 million Upfront Cash: $206.3 million
Deal Type: Divestment January 23, 2023
Details:
Clinigen confirms that Proleukin, interleukin-2 (aldesleukin), supplied for the MIROCALS trial, is currently licensed for metastatic renal cell carcinoma and melanoma in the US and metastatic renal cell carcinoma in certain other countries.
Lead Product(s): Aldesleukin,Riluzole
Therapeutic Area: Neurology Product Name: Proleukin
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2022
Details:
The combination also demonstrated the activation, mobilization, and proliferation of CD8 T cells and NKs, with slightly more modest effects on granulocytes, in most patients at lower ICT01 doses than shown in previously presented data of ICT01 monotherapy in a similar patient.
Lead Product(s): ICT01,Aldesleukin
Therapeutic Area: Oncology Product Name: ICT01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2.AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
AU-007 is a human monoclonal antibody computationally designed by Biolojic Design, with a highly differentiated approach to harnessing the power of interleukin-2 (IL-2) to eradicate solid tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biolojic Design
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 05, 2022
Details:
AU-007 is a computationally designed, human IgG1 monoclonal antibody that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, AU-007 leverages IL-2 to reinforce anti-tumor immune effects.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 27, 2022
Details:
The trial will evaluate AU-007, a highly differentiated monoclonal antibody that was computationally designed by Biolojic and harnesses the power of the body's own interleukin-2 (IL-2) to eradicate solid cancer tumors.
Lead Product(s): AU-007,Aldesleukin
Therapeutic Area: Oncology Product Name: AU-007
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Biolojic Design
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
According to the firm, the ODD recognises the potential therapeutic role of aldesleukin in treating disease, and could provide a number of benefits for Clinigen should it obtain a marketing approval for this indication.
Lead Product(s): Aldesleukin
Therapeutic Area: Neurology Product Name: Proleukin
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2020
Details:
OT-101 has demonstrated robust efficacy against pancreatic cancer, glioblastoma, and melanoma during phase 2 clinical trials. The demonstration that OT-101 will synergize with IL-2 further demonstrate its utility as adjunct to other immunotherapies.
Lead Product(s): Trabedersen,Aldesleukin
Therapeutic Area: Oncology Product Name: OT-101
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Autotelic BIO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 10, 2020
Details:
Proleukin will be made available by Clinigen in bulk supply over the course of a two-year period, ensuring that Iovance has uninterrupted access to Proleukin to continue ongoing clinical trials.
Lead Product(s): Aldesleukin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Iovance Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
